Riassunto
Le alterazioni del metabolismo minerale e del tessuto osseo rappresentano una complicazione comune nella storia naturale di numerose nefropatie, e trovano la loro espressione più tipica nei pazienti con insufficienza renale cronica in fase uremica (IRC). La comparsa di osteopatie metaboliche nei pazienti nefropatici è la conseguenza del ruolo chiave svolto dal rene nella regolazione dell’omeostasi minerale; infatti esso modula l’equilibrio esterno di calcio, fosforo e magnesio, controlla la sintesi di 1,25(OH)2D3, degrada e rimuove dal circolo l’ormone paratiroideo (PTH), contribuisce alla regolazione dell’equilibrio acido—base ed è il principale responsabile dell’escrezione di alluminio.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Bibliografia
Klawansky S, Klawansky S, Komaroff E et al (2003) Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14:570–576
de Deus RB, Ferreira AC, Kirsztajn GM (2003) Osteopenia in patients with glomerular diseases requiring long-term corticosteroid therapy. Nephron Clin Pract 94:69–74
Zonana-Nacach A, Roseman JM, McGwin G Jr et al (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808
Valderabbano F, Jones EHP, Mallick NP (1995) Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 10(Suppl):1–25
Caudarella R, Buffa A, Raffaella R, Vescini F (2005 ) Osteoporosi e malattie renali 5:296–301
Lemann J Jr, Adams ND, Wilz DR, Brenes LG (2000) Acid and mineral balances and bone in familial proximal renal tubular acidosis. Kidney Int 58:1267–1277
Kuemmerle N, Krieg RJ Jr, Latta K et al (1997) Growth hormone and insulin-like growth factor in non-uremic acidosis and uremic acidosis. Kidney Int 58:S102–S105
Green J, Maor G (2000) Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers. Kidney Int 57:2258–2267
Krieger NS, Sessler NE, Busbinsky DA (1992) Acidosis inhibit osteoblastic and stimulates osteoclastic activity in vitro. Med J Physiol 262:F185–F789
Bushinsky DA (1989) Net Calcium efflux from live bone during chronic metabolic, but not respiratory, acidosis. Am J Physiol 262:F836–F842
Coe FL, Firpo JJ Jr, Hollandsworth DL et al (1975) Effect of acute and chronic metabolic acidosis on serum immunoreactive parathyroid hormone in man. Kidney Int 8:262–273
Domrogkitchaiporn S, Pongsakul C (2001) Bone mineral density and histology in distal renal tubular acidosis. Kidney Int 59:1086–1093
Disthabanchong S, Domrongkitchaiporn S, Sirikulchayanonta V et al (2004) Alteration of noncollagenous bone matrix proteins in distal renal tubular acidosis. Bone 35(3):604–613
Vescini F, Buffa A, La Manna G et al (2005) Long-term potassium citrate therapy and bone mineral density in idiopathic calcium stone formers. J Endocrinol Invest 28: 218–222
Maghbooli Z, Hossein-Nezhad A, Adib HH et al (2007) Association between renal stone, bone mineral density and biochemical parameters. Iranian J Publ Health, Supplementary issue on osteoporosis, pp 45–50
Pak CYC, Britton F, Peterson R et al (1980) Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 69:19–30
Caudarella R, Vescini F, Buffa A et al (2004) Osteoporosis and urolithiasis. Urol Int 72(Suppl 1): 17–19
Lemann J Jr (2002) Idiopathic hypercalciuria. In: Coe FL and Favus MJ (eds) Disorders of bone and mineral metabolism. Lippincott Williams & Wilkins, Philadelphia, pp 673–697
Caudarella R, Vescini F, Buffa A et al (2003) Bone mass loss in calcium stone disease: focus on hypercalciuria and metabolic factors. J Nephrol 16:260–266
Jaeger P, Lippuner K, Casez JP et al (1994) Low bone mass in idiopathic renal stone formers: magnitude and significance. J Bone Miner Res 9:1525–1532
Fuss M, Gillet C, Simon J et al (1983) Bone mineral content in idiopathic renal stone disease and in primary hyperparathyroidism. Eur Urol 9(1):32–34
Bataille P, Achard JM, Fournier A et al (1991) Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 39(6): 1193–1205
Pietschmann F, Bresiau NA, Pak CYC (1992) Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Br Med Radiol 7:1383–1388
Trinchieri A, Nespoli R, Ostini F et al (1998) A study of dietary calcium and other nutrients in idiopathic renal calcium stone formers with low bone mineral content. J Urol 159(3):654–657
Institute of Medicine of the National Academy of Sciences (1994) Potassium. In: Dietary reference intakes for water, potassium, sodium, chloride and sulfate. National Academy Press, Washington, DC, pp 186–268
Caudarella R, Vescini F, Buffa, Stefoni S (2003) Citrate and mineral metabolism: kidney stones and bone disease. Front Biosci 8:s1084
Caudarella R, Vescini F (2008) Urinary citrate and renal stone diseases: the preventive role of alkali citrate treatment. Arch Ital Urol Androl 80:1–6
Melton LJ 3rd, Atkinson EJ, O’Fallon WM et al (1993) Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227–1233
Lauderdale DS, Thisted RA, Wen M, Favus MJ (2001) Bone mineral density and fracture among prevalent kidney stone cases in the Third National Health and Nutrition Examination Survey. J Bone Miner Res 16:1893–1898
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Italia
About this chapter
Cite this chapter
Caudarella, R., Vescini, F. (2009). Osteopatie metaboliche nelle malattie renali. In: Osteoporosi e malattie metaboliche dell’osso. Springer, Milano. https://doi.org/10.1007/978-88-470-1357-5_15
Download citation
DOI: https://doi.org/10.1007/978-88-470-1357-5_15
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1356-8
Online ISBN: 978-88-470-1357-5
eBook Packages: MedicineMedicine (R0)